Skip to content

Clinical application and immunological mechanism of vitamin D supplementation in repeated implantation failure

Clinical application and immunological mechanism of vitamin D supplementation in repeated implantation failure

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPC-17010606
Enrollment
Unknown
Registered
2017-02-09
Start date
2017-08-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Repeated implantation failure

Interventions

treatment group:Oral vitamin D
control group:None

Sponsors

Family Planning Research Institute,Tongji Medical College, Huazhong Science and Technology University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: All the subjects should be consistent with the diagnostic criteria of RIF, which has more than 3 times high quality embryo transplantation or multiple embryo number more than 10 pieces still failed to get clinical pregnancy. 1. Age 20 to 35 years old; 2. Previous menstrual regularity; 3. Normal function of uterus and ovary; 4. The couple is not associated with other diseases and have normal karyotype; 5. The voluntary have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. BMI>28 kg/m2; 2. Menstrual cycle third days FSH>10 mIU/ml; 3. Recurrent pregnancy loss (defined as 3 or more spontaneous abortions); 4. Had the uterine fibroids or endometriosis surgery; 5. Ultrasound diagnosis of ovarian endometriosis; 6. The cortisol therapy or other treatment for the immune system; 7. The autoimmune diseases, endocrine disorder disease, infectious disease, antiphospholipid syndrome, thrombotic state of anticoagulant therapy; 8. The congenital or acquired uterine anatomy abnormality; 9. hydrosalpinx; 10. In the vitamin D treatment; 11. Had serious cardiovascular disease, lung and liver and kidney disease; 12. Participated in other experimental drug research in screening within 3 months before the; 13. Researchers estimate the abnormal situation is not suitable for the group.

Design outcomes

Primary

MeasureTime frame
cell;cytokines;

Countries

China

Contacts

Public ContactLiao Aihua

Family Planning Research Institute, Tongji Medical College, Huazhong Science and Technology University

aihua_liao@sina.com+86 15994262573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026